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Abstract
We designed a crossover and placebo-controlled trial to investigate the impact of a 1-h acute vaping session of
nicotine-free and flavour-free e-liquid on the pulmonary functions and respiratory mechanics of healthy and asthmatic
individuals. This study shows that a 1-h vaping session of a high-grade and contaminant-free mixture of propylene
glycol and glycerol using a commercially available electronic cigarette performed in a controlled environment does not
significantly impact pulmonary functions, respiratory mechanics or symptoms in healthy or asthmatic subjects.
To the Editor,
Electronic cigarette (e-cigarette) use or ‘vaping’ has
stormed the world over the past years. It is available
everywhere and regardless of age, and is aggressively
marketed as a safe way to stop smoking despite a lack of
solid evidence. Reality is that we do not know the conse-
quences of vaping on pulmonary health and research is
urgently needed to identify potential health hazards.
While most emphasis is placed on nicotine and flavour-
ing agents found in e-liquid, very little scientific knowledge
is available on the acute effects of propylene glycol and
glycerol inhalation, the two compounds representing the
great majority of e-liquid total volume. We therefore aimed
at characterizing the acute effects of inhaling propylene
glycol and glycerol on lung functions. We were also inter-
ested to compare potential differences between volunteers
with no documented lung disease and volunteers with
diagnosed asthma, as the latter are generally more sensitive
to pulmonary irritants and bronchoconstrictive stimuli.
We conducted a randomized cross-over, placebo-
controlled study on the acute effect of nicotine-free and
flavour-free e-cigarette vapor inhalation. Volunteers
were aware of using full (experimental) or empty
(placebo) e-cigarettes as no vapors were coming out of
the empty placebo device. The e-liquid consisted of a
mixture of 70% USP-grade propylene glycol (PG) and
30% USP-grade glycerol (Gly), mixed in our laboratory
under a biosafety cabinet. This 70%PG/30%Gly mixture
is largely representative of what is used on the market
to dissolve nicotine and/or flavours. Our approach was
to create the best-case scenario, where unwanted and
possibly harmful contaminants are absent, to specific-
ally investigate the pulmonary effects of PG and Gly.
Twenty healthy volunteers and ten asthmatic volun-
teers were recruited for the trial. Healthy volunteers
were aged between 20 and 37 years, had no docu-
mented lung disease and had normal response to
methacholine. Asthmatic volunteers were aged between
21 and 40 years and all had received a diagnosis of
asthma and had airway hyperresponsiveness as shown
by a positive methacholine challenge. All volunteers
were non-smokers and none were active e-cigarette
users. Moreover, none of the volunteers were exposed
to secondary tobacco or e-cigarette vapors at home. All
volunteers gave their written informed consent and the
IUCPQ-UL Ethics Board approved the trial (reference
number 2015–2459 21256).
The experimental and placebo sessions took place 1
week apart. A preceding visit was also planned, where
baseline measurements were taken (i.e. vital signs, lung
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functions, airway resistance measurements), a methacho-
line challenge was performed according to Juniper et al.
[1], and volunteers were familiarized with the e-cigarette.
On the following two sessions (experimental and placebo),
volunteers were asked to inhale three times per minute, in
sitting position, for a total duration of 1 hour. Respiratory
mechanics and lung functions were measured by the
forced oscillation technique (TremoFlow) and spirometry,
respectively and in that order, immediately before (T0),
immediately after (T60), and 30 min after (T90) the
inhalation sessions. Respiratory symptoms were collected
according to the Borg perception scale at the same time
points as well as every 20 min during the inhalation
session. The fraction of exhaled nitric oxide (FeNO) and
serum C-reactive protein (CRP) were also measured in
asthmatic volunteers. FeNO and serum samples were not
collected in non-asthmatic volunteers.
All volunteers were able to complete the sessions. Data col-
lected are presented in Table 1. A few subjects noticed symp-
toms when using the loaded e-cigarette including cough,
chest tightness, and secretions, but no consensual differences
in symptoms were noticed in healthy or asthmatic volunteers.
Changes in vital signs such as oxygen saturation, heart rate,
and breathing frequency were not different between placebo
or experimental sessions. No changes in lung functions were
observed using either spirometry or forced oscillation tech-
nique. Finally, signs of flaring inflammation, such as increased
FeNO and serum CRP levels, were not observed in response
to e-cigarette in the asthmatic group.
This study shows that a 1-h inhalation session of a
high-grade and contaminant-free mixture of propylene
glycol and glycerol using a commercially available e-
cigarette performed in a controlled environment does
not significantly impact pulmonary function or symp-
toms in both healthy and asthmatic subjects. This is
consistent with Ferrari et al. [2] and Flouris et al. [3].
The latter showed in healthy individuals that inhalation
sessions of 5 or 30 min, respectively, had no significant
effects on lung functions measured by spirometry.
An unavoidable limitation of this study and similar
studies is that individuals are aware of using the full or
empty e-cigarette. It is simply impossible to blind the indi-
viduals since the e-liquid has an off-taste and produces a sig-
nificant amount of visible vapors. Subjective measures such
as symptoms could have been affected by this limitation, but
we believe that the objective physiological measures (i.e.
spirometry, forced oscillation technique) were not affected.
Therefore, while acute exposure to e-cigarette vapors
does not seem to cause significant functional pulmonary
alterations in healthy and asthmatic individuals, there is
an urgent need to study the effects of chronic use, espe-
cially in more susceptible populations such as teenagers,
smokers, and individuals with chronic lung diseases such
as asthma and chronic obstructive pulmonary disease.
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Take home message
An acute 1-h use of nicotine-free and flavour-free e-cigarette does not
significantly affect lung functions of healthy and asthmatic individuals.
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